高危早期三阴性乳腺癌患者的多重高通量免疫细胞成像:国际乳腺癌研究组(IBCSG)22-00试验分析
该研究基于IBCSG 22-00随机III期试验的病例队列样本,用6色免疫荧光染色刻画TNBC患者的免疫细胞浸润。高CD3+ T细胞及间质和上皮内Tregs浸润与更好的远处无复发生存间期(DRFI)相关,尤其在淋巴结阳性患者中;基线免疫细胞空间分布关键,CM维持治疗对T细胞排斥的淋巴结阳性TNBC患者不利。
要点
- 高CD3+ T细胞及间质和上皮内Tregs浸润与更好的DRFI相关,尤其在淋巴结阳性患者中。
- 基线免疫细胞空间分布至关重要,CM维持治疗对T细胞排斥的淋巴结阳性TNBC患者不利。
- 免疫空间分类可能有助于临床试验患者选择并改善特定治疗反应。
核心结论
- 免疫细胞浸润的空间分类似乎至关重要,可能有助于临床试验中的患者选择并大幅改善对特定疗法的反应。
研究设计与样本
- IBCSG 22-00是一项随机III期临床试验,测试低剂量节拍口服环磷酰胺-甲氨蝶呤(CM)维持治疗在早期激素受体阴性乳腺癌标准辅助化疗后的疗效。
- 采用病例队列抽样,用6色免疫荧光染色(CD4、FOXP3、CD3、细胞角蛋白和CD8)刻画TNBC患者的免疫细胞浸润。
主要发现
- 高免疫CD3+ T细胞以及间质和上皮内Tregs(CD4+Foxp3+ T细胞)浸润与更好的远处无复发生存间期(DRFI)相关,尤其在淋巴结阳性患者中,与治疗无关。
- 基线免疫细胞的空间分布至关重要,CM维持治疗对T细胞排斥的淋巴结阳性TNBC患者不利。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer (BC) subtype, with dismal prognosis and limited option in advanced settings, yet stromal tumor infiltrating lymphocytes (sTILs) in this subtype has a predictive role. PATIENTS AND METHODS: The International Breast Cancer Study Group (IBCSG) Trial 22-00 is a randomized phase III clinical trial testing the efficacy of low-dose metronomic oral Cyclophosphamide-Methotrexate (CM) maintenance following standard adjuvant chemotherapy treatment for early-stage hormone receptor-negative breast cancer patients. A case-cohort sampling was used. We characterized immune cells infiltrates in patients with TNBC by 6 plex immunofluorescence (IF) staining for CD4, FOXP3, CD3, cytokeratine and CD8 RESULTS: We confirmed that high immune CD3+ T cells as well as stromal and intra-epithelial Tregs (CD4+Foxp3+ T cells) infiltrates were associated with a better Distant Recurrence-Free Interval (DRFI), especially in LN+ patient, regardless of the treatment. More importantly, we showed that the spatial distribution of immune cells at baseline is crucial, as CM maintenance was detrimental for T cells excluded LN+ TNBC patients. CONCLUSIONS: immune spatial classification on immune cells infiltrates seems crucial and could help patients' selection in clinical trial and greatly improve responses to specific therapies.
引用
- Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, et al. Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00. Eur J Cancer. 2024. PMID: 38309015. doi:10.1016/j.ejca.2024.113535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。